Zomdf.Pk
ZOMDF.PK operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development, manufacturing, and distribution of pharmaceutical products.
Business. ZOMDF.PK operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development, manufacturing, and distribution of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ZOMDF.PK operates in the healthcare sector, specifically in the pharmaceuticals industry, and generates revenue primarily through the development, manufacturing, and distribution of pharmaceutical products.
ZOMDF.PK has a capital structure with no long-term debt and a debt-to-equity ratio of 0.0, indicating a fully equity-funded operation. The company holds $9,017,000 in cash and equivalents, and its current ratio of 6.78 suggests strong short-term liquidity. However, the company reported negative operating and free cash flows of -$17,649,000 and -$74,853,000, respectively, indicating significant cash outflows from operations.
Profitability metrics for ZOMDF.PK are negative, with a return on equity of -70.94% and a return on assets of -64.44%, both well below the industry median for pharmaceuticals. The company reported a net loss of -$81,858,000 and an operating loss of -$84,353,000, which is a significant deviation from the typical earnings profile of firms in the sector.
ZOMDF.PK's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided in the available data. This lack of diversification may expose the company to higher operational and market risks, particularly in the pharmaceuticals industry where regulatory and market dynamics can vary significantly by region.
The company's growth trajectory is currently negative, with a net loss and declining cash flows. Analysts have recorded a last actual revenue of $32,030,000, but no forward-looking revenue guidance is available to assess future performance. The absence of capital expenditures and the lack of dilution risk suggest the company is not currently investing in expansion or restructuring.
ZOMDF.PK faces low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating and free cash flows raise concerns about its ability to sustain operations without external financing. No dilution sources were identified in the available documents, and the company has not issued shares recently.
Recent filings and transcripts do not provide additional insights into the company's operations or strategic direction. The absence of recent disclosures may limit the visibility into management's plans for addressing the company's financial challenges.
- ZOMDF.PK is a pharmaceutical company with no long-term debt and a strong current ratio of 6.78, but it is experiencing significant cash outflows and losses.
- The company's return on equity and return on assets are -70.94% and -64.44%, respectively, indicating poor profitability relative to industry norms.
- ZOMDF.PK's revenue is concentrated in a single segment, and no geographic breakdown is available, which may increase operational risk.
- The company is not currently investing in capital expenditures and has no immediate dilution risk, but its negative cash flows raise concerns about liquidity.
- Analysts have recorded a last actual revenue of $32,030,000, but no forward-looking guidance is available to assess future performance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ZOMDF.PK Market data — financials · 2026-05-30
- Zomedica Corp Market data — analyst estimates · 2026-05-30
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$1M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -60.0%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -60.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -0.5%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -38.7%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -41.0%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 17.4%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -1.4%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -65.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 25.3%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 28.4%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -89.1%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 26.3%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 13.6%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -74.2%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.10xDerived (calculated)
- Net margin (FY 2025-12-31): -255.6%Derived (calculated)
- Gross margin (FY 2025-12-31): 67.7%Derived (calculated)
- Return on equity (FY 2025-12-31): -70.9%Derived (calculated)
- Current ratio (FY 2025-12-31): 6.78xDerived (calculated)
- Return on assets (FY 2025-12-31): -64.4%Derived (calculated)
- Cash & equivalents (annual): USD 9.02MSEC XBRL filing
- Operating income (annual): USD -84.35MSEC XBRL filing
- Shareholders' equity (annual): USD 115.4MSEC XBRL filing
- Capex (annual): USD 567KSEC XBRL filing